Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Lipocine Inc. Investors and Encourages Investors to Contact the Firm

LPCN

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Lipocine Inc. Investors and Encourages Investors to Contact the Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN) securities between February 27, 2015 and June 28, 2016, inclusive (the “Class Period”).

If you are a member of the Class described above, you have until August 30, 2016 to move the Court to appoint you as lead plaintiff. Please contact the Law Offices of Howard G. Smith to discuss your legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

Throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company improperly designed and implemented its NDA for LPCN 1021; (2) that, as a result, the FDA would deny or delay approval of the Company’s lead product candidate; (3) that, as a result of the foregoing, the Company’s future revenues and viability would be jeopardized; and (4) that, as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Lipocine’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you purchased shares of Lipocine during the Class Period you may move the Court no later than August 30, 2016 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today